G. Davis

657 total citations
11 papers, 240 citations indexed

About

G. Davis is a scholar working on Hepatology, Epidemiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, G. Davis has authored 11 papers receiving a total of 240 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hepatology, 6 papers in Epidemiology and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in G. Davis's work include Hepatitis C virus research (7 papers), Liver Disease Diagnosis and Treatment (5 papers) and Hepatitis B Virus Studies (4 papers). G. Davis is often cited by papers focused on Hepatitis C virus research (7 papers), Liver Disease Diagnosis and Treatment (5 papers) and Hepatitis B Virus Studies (4 papers). G. Davis collaborates with scholars based in United States, Germany and France. G. Davis's co-authors include Tomoyoshi Ohno, Johnson Y.N. Lau, David R. Nelson, Constantine G. Marousis, Randi Streisand, Michael G. Perri, James R. Rodrigue, Samuel F. Sears, John B. Wong and Stephen G. Pauker and has published in prestigious journals such as Hepatology, The Journal of Infectious Diseases and Journal of Hepatology.

In The Last Decade

G. Davis

11 papers receiving 230 citations

Peers

G. Davis

HEPAT

EPIDE

RHEUM

IMMUN

VIROL

Ana M. Contreras Mexico

Patricia González Spain

S. García‐Garzón Spain

Maria Clotilde Ragni Italy

Norma de Paula Cavalheiro Brazil

Arthur Kim United States

Francisco Socas Gavilán Spain

S Iwasaki Japan

I. Guarnori Italy

Evelyn Crewe Australia

Ana M. Contreras Mexico

G. Davis

175 ×0.9

HEPAT

166 ×1.2

EPIDE

17 ×0.4

RHEUM

13 ×0.3

IMMUN

16 ×0.9

VIROL

Citations per year, relative to G. Davis G. Davis (= 1×) peers Ana M. Contreras

Countries citing papers authored by G. Davis

Since Specialization

Citations

This map shows the geographic impact of G. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Davis more than expected).

Fields of papers citing papers by G. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Davis. The network helps show where G. Davis may publish in the future.

Co-authorship network of co-authors of G. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of G. Davis. A scholar is included among the top collaborators of G. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Davis. G. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Buti, Marı́a, Robert Flisiak, J. Rasenack, et al.. (2013). 1421 ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS). Journal of Hepatology. 58. S572–S572. 2 indexed citations

Alberti, Antonio, Wan‐Long Chuang, Robert Flisiak, et al.. (2012). 1406 ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR. Journal of Hepatology. 56. S553–S554. 12 indexed citations

Rustgi, V., Vijayan Balan, Mark Sulkowski, et al.. (2006). 113 A phase 2 dose-escalation study of albuferon combined with ribavirin in non-responders to prior interferon-based therapy for chronic hepatitis C infection. Journal of Hepatology. 44. S50–S50. 13 indexed citations

Wong, John B., William Rosenberg, M.P. Manns, et al.. (2003). Evaluating rapid virological response reduces ribavirin and peginterferon alfa-2B treatment costs for chronic hepatitis C in the United Kingdom. Journal of Hepatology. 38. 181–182. 3 indexed citations

Wong, John B., William Rosenberg, M.P. Manns, et al.. (2003). Is peginterferon alfa-2B plus ribavirin cost-effective for treating chronic hepatitis C in the United Kingdom?. Journal of Hepatology. 38. 181–181. 1 indexed citations

Poynard, Thierry, et al.. (2001). Durability of viral response to interferon ribavirin combination in patients with chronic hepatitis C. Journal of Hepatology. 34. 23–23. 9 indexed citations

Streisand, Randi, et al.. (1999). A Psychometric Normative Database for Pre-Liver Transplantation Evaluations. Psychosomatics. 40(6). 479–485. 39 indexed citations

Nelson, David R., Constantine G. Marousis, Tomoyoshi Ohno, G. Davis, & Johnson Y.N. Lau. (1998). Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology. 28(1). 225–230. 117 indexed citations

Bennett, William G., Stephen G. Pauker, G. Davis, & John B. Wong. (1996). Modeling therapeutic benefit in the midst of uncertainty. Digestive Diseases and Sciences. 41(S12). 56S–62S. 18 indexed citations

10.

Davis, G.. (1991). Loss of HBsAg after interferon-α treatment: Cure of chronic hepatitis B virus?. Hepatology. 14(5). 953–954. 1 indexed citations

11.

Douglas, Jacinta, G. Davis, Michael Remington, et al.. (1988). A Double-Blind, Placebo-Controlled Trial of the Effect of Chronically Administered Oral Acyclovir on Sperm Production in Men With Frequently Recurrent Genital Herpes. The Journal of Infectious Diseases. 157(3). 588–592. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact